The significant increase in the price target from $8 to $21 by a reputable analyst at Barclays suggests a strong bullish outlook on Solid Biosciences. This adjustment reflects positive expectations for the company's future performance, likely based on recent developments or financial results. Such a substantial revision typically leads to increased investor confidence and can drive the stock price up in the short term.